- Abu Dhabi Will Aid Debt-Fraught Dubai 'Case by Case'
- Banks With The Biggest Exposure to The UAE
- Dubai's Debt Woes Signal New Era for Creditors
- Next Week: Cash In Now Or Wait For A Santa Rally?
- Dubai Stock Selloff May Bring Buying Opportunity
- Longer Lines, Fuller Carts This Black Friday
- Big US Banks May Be Forced to Raise Capital: Bove
- Bank of America Amends Pay for Senior Executives
- Tiger Woods Out of Hospital After Accident
- U.S. Stocks Fall on Dubai Worries
- Black Friday at Best Buy
- Strategists on Dubai: Avoid 'Rash Moves' Now
- Longer Lines, Fuller Carts This Black Friday
- Dubai Stock Market Fear Has 'Legs': Dennis Gartman
- Obama's Emission Reduction Pledge Paints Future for Autos
- Is Super Bowl Halftime Act Too Old?
- Surprising Options Trades in TiVo Shares
- EA Sports Hopes to Pump Up Sales Through Pop-Up Locations
MOST SHARED
- Tiger Woods Out of Hospital After Accident
- The Good Entrepreneur Winner
- Gold Will Collapse Like Oil Did in 2008: Charts
- Abu Dhabi Will Aid Debt-Fraught Dubai 'Case by Case'
- Halftime Report: Dubai - First Ripple Of Larger Crisis?
- CNBC VIDEO: Warren Buffett & Bill Gates 'Walk & Talk' at Columbia University
Text Size 
Baxter [BAX
Loading...
()
] researchers revealed positive mid-stage test results on an intravenous drug, Gammagard, that's already in late-stage development in a very small number of patients.
According to test reports, the plasma-based drug appears to improve memory and quality of life—or at the very least, stabilize and stop the rate of loss of memory.
Baxter's stock rose almost 2 percent when the data was released. (See the accompanying video for more.)
Meanwhile, Elan [ELN
Loading...
()
] and Wyeth’s [WYE
Loading...
()
] shares plunged Wednesday after word that mid-stage test results on a potentially first-of-its-kind Alzheimer’s drug, Bapineuzumab, raised safety issues.
However, Elan CEO Kelly Martin told CNBC he was confident in Bapineuzumab.
"There are obviously some gaps between the market interpretation and what we know,” Martin said.
Additionally, a small biofirm, Medivation [MDVN
Loading...
()
], showed new data on an anti-histamine that in a large study appears to preserve memory in mild to moderate Alzheimer’s patients.
Print
Email
- These four sectors will be the next to lead the market.
- Zhu Zhu Pets are this year's must-have toy, fetching $40 or more on eBay.
- From the why-didn’t-I-think-of-that file, we present Jason Sadler, a man whose job is wearing T-shirts.
- It may be the most unusual guide to business you'll read.
- Shopping for a gadget hound? The choices can be baffling. Here are a few that should be a hit.
- "The Who" will be the halftime act for Super Bowl XLIV on Feb. 7 in Miami. Is the NFL behind the times?
Data is a real-time snapshot *Data is delayed at least 15 minutes